I joined Rutgers Cancer Institute of New Jersey as Co-Director of the Blood and Marrow Transplant Program in January 2016 after spending more than 30 years at the Yale Cancer Center. Prior to joining the Medical Oncology Faculty, I did my internship, residency and fellowship at Yale-New Haven Hospital and spent one year at the University of Pittsburgh as a Chief Resident in Internal Medicine. I became the Director of the Yale Stem Cell Transplant Program in 1997 and remained in that position for over 15 years. I am also affiliated with RWJ University Hospital. In addition to caring for patients undergoing autologous and allogeneic transplants, my major areas of clinical expertise are multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphoma. While at Yale and under my direction, we became one of the first programs in the US to offer outpatient autologous stem cell transplants. I am even prouder of our survival statistics after allogeneic (donor) transplantation as they have typically been at or near the top of those from the entire country. I believe that the latter is representative of building a strong team with each member committed to the best possible patient outcome.
I am the author or co-author of 56 peer-reviewed original manuscripts, mostly centered on patient management of patients with lymphoma and myeloma or after a stem cell transplant. My major motivation in coming to the Rutgers Cancer Institute of New Jersey was to work with individuals, many of whom I had known for over a decade, who shared the same commitment to clinical excellence and investigation as I do. In addition, as a National Cancer Institute-Designated Comprehensive Cancer Centers, Rutgers Cancer Institute provides a tremendously rich academic environment that facilitates cutting-edge therapies for hematologic malignancies.